Ozempic
semaglutide
- Strength
- .68 mg/mL
- Form
- Injection, Solution
- Class
- GLP-1 Receptor Agonist
Novo Nordisk Pharmaceutical Industries, LP
OZEMPIC
oral semaglutide
Listed by Novo Nordisk Pharmaceutical Industries, LP
- Strength
- 9 mg/1
- Form
- Tablet
- Route
- Oral
- Class
- GLP-1 Receptor Agonist
What it contains
- Semaglutide 9 mg/1
FDA record
| Dosage form | Tablet |
|---|---|
| Route | Oral |
| Drug class | GLP-1 Receptor Agonist |
| Approval route | NDA — original brand approval |
| NDC code | 0169-1709 |
| FDA application | NDA213051 |
| Marketed since | April 2026 |
Other products containing Semaglutide
See allSame active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Ozempic
semaglutide
- Strength
- 1.34 mg/mL
- Form
- Injection, Solution
- Class
- GLP-1 Receptor Agonist
Novo Nordisk Pharmaceutical Industries, LP
OZEMPIC
oral semaglutide
- Strength
- 4 mg/1
- Form
- Tablet
- Class
- GLP-1 Receptor Agonist
Novo Nordisk Pharmaceutical Industries, LP
Ozempic
semaglutide
- Strength
- 1.34 mg/mL
- Form
- Injection, Solution
- Class
- GLP-1 Receptor Agonist
A-S Medication Solutions
Ozempic
semaglutide
- Strength
- 2.68 mg/mL
- Form
- Injection, Solution
- Class
- GLP-1 Receptor Agonist
Novo Nordisk Pharmaceutical Industries, LP
OZEMPIC
semaglutide
- Strength
- 2.68 mg/mL
- Form
- Injection, Solution
- Class
- GLP-1 Receptor Agonist
A-S Medication Solutions
Ozempic
semaglutide
- Strength
- .68 mg/mL
- Form
- Injection, Solution
- Class
- GLP-1 Receptor Agonist
A-S Medication Solutions
OZEMPIC
oral semaglutide
- Strength
- 1.5 mg/1
- Form
- Tablet
- Class
- GLP-1 Receptor Agonist
Novo Nordisk Pharmaceutical Industries, LP
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.